Untamed Mustang Winner Announced
Gilroy
– Bob Lynch Ford-Lincoln-Mercury’s
”
Untamed
”
Mustang Sweepstakes enters its final countdown. The dealership
announced it’s fourth winner of $500 recently. Warren Gasper, Jr.,
of San Jose, who was one of four family members who entered the
drawing, was notified of his good fortune.
Untamed Mustang Winner Announced
Gilroy – Bob Lynch Ford-Lincoln-Mercury’s “Untamed” Mustang Sweepstakes enters its final countdown. The dealership announced it’s fourth winner of $500 recently. Warren Gasper, Jr., of San Jose, who was one of four family members who entered the drawing, was notified of his good fortune.
The sweepstakes continued with monthly drawings for $500, culminating in a drawing today for a 2-year lease of a 2006 Mustang GT.
For more information, visit www.BobLynchFord.com or register at the dealership, 6290 Monterey Highway.
Interest in MP3 players grows
San Jose – Shutterbugs, time to face the music. Portable digital music players are now on par with digital cameras as the most wanted electronics items, a new survey finds.
More than one in five U.S. consumers, or 22 percent, say they plan to buy an MP3 player in the next three months, up from 13 percent from last year, according to the Ipsos Insight survey. Meanwhile, digital cameras held steady at 22 percent for the third year in a row.
A new category – portable multimedia devices, such as the newer iPods that can display photos or video besides playing music – also jumped into the mix this year, with 14 percent of consumers expressing interest in buying one.
Interest in cell phones and personal computers dropped this year, though at 20 percent and 21 percent, respectively, they remain high on wish lists.
Titan acquires Amgen Inc.
San Francisco – Biotechnology titan Amgen Inc. said Wednesday it has agreed to acquire Abgenix Inc. for $2.2 billion in cash and the assumption of debt.
Abgenix, based in Fremont, is a small biotechnology company that genetically engineers mice to produce potential cancer drugs.
If the deal is approved by both companies’ boards and regulators, Abgenix shareholders will receive $22.50 a share – a 54 percent premium over its closing stock price of $14.65 Wednesday.
Amgen said Wednesday that it believes sales of the still-experimental drug called panitumumab could exceed $2 billion a year.
